Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma Who Have Received Prior Systemic Anticancer Therapy

NCT03586973 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03586973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03586973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma Who Have Received Prior Systemic Anticancer Therapy
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
August 6, 2018
Completion date
June 29, 2021
Enrollment
34 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma